CRISPR BY DESIGN
Live / Applied — Non-final action mailed (as of 13 Mar 2026)
What this means for you
Not registered yet, but its 08 Aug 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99328121
- Mark type
- Stylized text
- Filed
- 08 Aug 2025
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in prevention, and treatment of diseases in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders.
- Class 044 — Medical, beauty and agricultural services: Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions.
Owner
- Scribe Therapeutics Inc., Alameda, CA, US
Prosecution history
- 13 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Mar 2026 — NON-FINAL ACTION E-MAILED
- 13 Mar 2026 — NON-FINAL ACTION WRITTEN
- 12 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 11 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 26 Dec 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 26 Dec 2025 — NON-FINAL ACTION E-MAILED
- 26 Dec 2025 — NON-FINAL ACTION WRITTEN
- 22 Dec 2025 — ASSIGNED TO EXAMINER
- 18 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 08 Aug 2025 — APPLICATION FILING RECEIPT MAILED
- 08 Aug 2025 — NEW APPLICATION ENTERED